Table 1 TMEM16A expression and function in cancers
From: Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer
Author/year | Cancer type | Cancer cells | Human samples | |||||
|---|---|---|---|---|---|---|---|---|
Cell lines | Overexpression mechanism | Signaling pathways | Proliferation | Migration | Expression | Clinical outcome of overexpression | ||
Britschgi et al./2013 [42] | Breast cancer | ZR75–1, HCC1954, MDA-MB-415 | 11q13 amplification | EGFR CAMKII | + | NR | High expression due to gene amplification | Poor survival |
Wu et al./2015 [43] | Breast cancer | NR | NR | NR | NR | NR | High expression | Good prognosis in PR+ or HER2− breast cancer patients following tamoxifen treatment |
Wu et al./2017 [95] | Breast cancer | MCF-7, MDA-MB-435S | NR | NR | + (MCF-7) - (MDA-MB-435S) | NR | High expression | Good prognosis in PR+ or HER2− breast cancer patients the low expression of Ki67 |
Ubby et al./2013 [94] | Breast cancer | HEK293 cells transfected with TMEM16A | NR | NR | No effect | No effect | mRNA isoforms similar to normal tissue | NR |
Duvvuri et al./2012 [44] | HNSCC | UM-SCC1 | 11q13 amplification | Ras-Raf-Mek-ERK1/2 | + | NR | High expression | Poor survival |
Ruiz et al./2012 [45] | HNSCC | BHY | 11q13 amplification | NR | No effect | + | High expression due to gene amplification | Poor survival |
Ayoub et al./2010 [46] | HNSCC | HEp-2 SCC-25 | NR | NR | No effect | + | High expression due to gene amplification | Distal metastasis |
Shiwarski et al./2014 [74] | HNSCC | UM-SCC1 | Low expression of TMEM16A via promoter hypermethylation | NR | NR | – | High expression in primary tumor and low expression in nodal metastatic tissue | NR |
Rodrigo et al./2015 [47] | HNSCC | NR | NR | NR | NR | NR | High expression due to gene amplification | No correlation with clinical parameter; affects patient’s survival depending on tumor’s site. |
Dixit et al./2015 [73] | HNSCC | HPV-negative FaDu PE/CE-PJ34 | NR | NR | + | NR | High expression in HPV-negative HNSCC via promoter hypomethylation | Decreased survival in HPV-negative HNSCC |
Bill et al./2015 [79] | HNSCC | Te11 | 11q13 amplification | EGFR signaling | + | NR | NR | NR |
Wanitchakool et al./2017 [59] | HNSCC Colon cancer | BHY, CAL33 HT29, T84 | 11q13 amplification Epigenetic regulation by HDAC | NR | + (BHY, CAL33) - (HT29) | + | NR | NR |
Shi et al./2013 [50] | ESCC | KYSE30 KYSE510 | 11q13 amplification | NR | + | NR | High expression due to gene amplification | Lymph node metastasis and advance clinical stage |
Cha et al./ 2015 [71] | Prostate cancer | PC3 LnCap | Transcriptional regulation by testosterone | AKT activation | + | NR | High expression | NR |
Matsuba et al./2014 [77] | Prostate cancer Breast cancer | PC-3 LNCaP YMB1 | Epigenetic regulation by HDAC | NR | + | NR | NR | NR |
Mokutani et al./2016 [49] | Colorectal cancer | DLD-1 HCT116 | miR-132 downregulation | NR | NR | NR | High expression due to low expression of miR-132 | Poor survival |
Sui et al./ 2014 [48] | Colorectal cancer | SW620, HCT116 LS174T | Gene amplification | MAPK (MEK and ERK1/2) signaling | + | + | NR | NR |
Cao et al./2017 [55] | Gastric cancer | AGS BGC823 | MiR-381 downregulation | TGFβ signaling | NR | + | High expression due to miR-381 downregulation | Metastasis and poor prognosis |
Deng et al./2016 [52] | Hepatocellular carcinoma | SMMC-7721 | NR | MAPK (p38 and ERK1/2) signaling | + | + | High expression | NR |
Liu et al./2014 [56] | Glioma | U87MG U251 SHG44 U118 | NR | NFκB | + | + | High expression | NR |
Jia et al./2015 [51] | Lung cancer | GLC82 NCI-H520 | NR | NR | + | + | High expression | NR |
Sauter et al./ 2015 [92] | Pancreatic ductal adenocarcinoma | BxPC-3, AsPC-1, Capan-1 | NR | NR | No effect | + | NR | NR |
Simon et al./2013 [93] | GIST | GIST-T1 GIST-882 | NR | NR | No effect | NR | NR | NR |
Liu et al./2015 [54] | Gastric cancer | AGS BGC-823 | NR | TGF-β signaling | No effect | + | High expression | Poor prognosis |